Positives

• The original Erlangen glaucoma patient who serendipitously had Long COVID described his pre-treatment state as “completely disoriented and unfocused… a shadow of my former self, a zombie” and reported substantial symptom improvement within one week of a single 75-minute BC007 infusion, with improvements persisting for months Health Rising.
  
  
• A formerly very athletic patient (cross-country skier and ex-Ironman) with severe brain fog, inability to follow conversations, panic attacks, and complete dependency reported substantial symptom resolution after BC007 infusion, with improvements maintained beyond several months Health Rising.
  
  
• A trial participant named Shayna Bhalla described her response as “In the last few months, I have literally regained life,” resuming university classes and daily activities after years of debilitating fatigue, headaches, and neurological issues The Sick Times.
  
  
• A third compassionate-use patient (a previously avid exerciser who had been bedridden with episodes of temporary paralysis) showed marked symptom improvement after BC007 infusion, with benefits sustained for at least several months Health Rising.
  
  

Negatives

• When the Phase 2 trial ended, Shayna Bhalla said: “I feel like I’m back at zero” — capturing the experience of patients whose post-trial access to the drug was cut off The Sick Times.
  
  
• A trial participant named Claudia noted the unreliability of the autoantibody screening biomarker, observing participants “got screened at multiple screening sites multiple times… until they finally got a positive result” The Sick Times.
  
  

Hurdles & Side Effects

• Berlin Cures (the company developing BC007) entered insolvency proceedings in 2024 following the failed Phase 2 readout, casting serious doubt on the future availability of the drug Reddit.
  
  
• Trial participant Emma reported that the standardized survey tools used to measure outcomes did not adequately reflect post-exertional malaise patients’ experience The Sick Times.